MJ Pharma: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
MJ Pharma
Largest movements
- Receivables within one year -€77,015
down €77,015 (-59.8%), from €128,802 to €51,787
of which Other amounts receivable: -€77,015
- Cash -€7,532
down €7,532 (-66.3%), from €11,367 to €3,835
mainly Contributions, distributions and other (-€105,472) and Debts after one year (-€48,287)
- Debts after one year -€48,287
down €48,287 (-20.2%), from €239,157 to €190,870
- Reserves -€44,384
down €44,384 (-13.9%), from €319,111 to €274,728
- Tax, wage and social debts +€16,962
up €16,962 (+1,394%), from €1,217 to €18,179
- Trade debts -€9,446
down €9,446 (-99.7%), from €9,476 to €30
- Financial income -€44,854
down €44,854 (-78.0%), from €57,500 to €12,646
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €619,294 | €534,747 | -€84,547 | -13.7% |
| Fixed assets | 21/28 | €479,125 | €479,125 | = | 0.0% |
| Financial fixed assets | 28 | €479,125 | €479,125 | = | 0.0% |
| Current assets | 29/58 | €140,169 | €55,622 | -€84,547 | -60.3% |
| Amounts receivable within one year | 40/41 | €128,802 | €51,787 | -€77,015 | -59.8% |
| Trade receivables | 40 | €7,260 | €7,260 | = | 0.0% |
| Other amounts receivable | 41 | €121,542 | €44,527 | -€77,015 | -63.4% |
| Cash at bank and in hand | 54/58 | €11,367 | €3,835 | -€7,532 | -66.3% |
| Total equity and liabilities | 10/49 | €619,294 | €534,747 | -€84,547 | -13.7% |
| Equity | 10/15 | €321,611 | €277,228 | -€44,384 | -13.8% |
| Contributions | 10/11 | €2,500 | €2,500 | = | 0.0% |
| Reserves | 13 | €319,111 | €274,728 | -€44,384 | -13.9% |
| Distributable reserves | 133 | €319,111 | €274,728 | -€44,384 | -13.9% |
| Amounts payable | 17/49 | €297,683 | €257,520 | -€40,163 | -13.5% |
| Amounts payable after more than one year | 17 | €239,157 | €190,870 | -€48,287 | -20.2% |
| Financial debts | 170/4 | €239,157 | €190,870 | -€48,287 | -20.2% |
| Amounts payable within one year | 42/48 | €58,526 | €66,650 | +€8,124 | +13.9% |
| Current portion of amounts payable after more than one year | 42 | €47,679 | €48,287 | +€608 | +1.3% |
| Trade debts | 44 | €9,476 | €30 | -€9,446 | -99.7% |
| Suppliers | 440/4 | €9,476 | €30 | -€9,446 | -99.7% |
| Taxes, remuneration and social security | 45 | €1,217 | €18,179 | +€16,962 | +1,394% |
| Taxes | 450/3 | €1,217 | €18,179 | +€16,962 | +1,394% |
| Other amounts payable | 47/48 | €154 | €154 | = | 0.0% |
| Other operating charges | 640/8 | €590 | €607 | +€17 | +2.9% |
| Gross operating margin | 9900 | €68,702 | €68,664 | -€38 | -0.1% |
| Operating profit (loss) | 9901 | €68,112 | €68,057 | -€55 | -0.1% |
| Financial income | 75/76B | €57,500 | €12,646 | -€44,854 | -78.0% |
| Recurring financial income | 75 | €57,500 | €12,646 | -€44,854 | -78.0% |
| Financial charges | 65/66B | €4,149 | €3,466 | -€682 | -16.4% |
| Recurring financial charges | 65 | €4,149 | €3,466 | -€682 | -16.4% |
| Profit (loss) for the period before taxes | 9903 | €121,463 | €77,236 | -€44,227 | -36.4% |
| Income taxes | 67/77 | €15,991 | €16,148 | +€157 | +1.0% |
| Profit (loss) for the period | 9904 | €105,472 | €61,088 | -€44,384 | -42.1% |
| Profit (loss) for the period to be appropriated | 9905 | €105,472 | €61,088 | -€44,384 | -42.1% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 29 October 2026 via checked.be.